| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1999;34:617-624.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
In Vivo Study of AT1 and AT2 Angiotensin Receptors in Apoptosis in Rat Blood Vessels
From the Medical Research Council of Canada Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
Correspondence to Ernesto L. Schiffrin, MD, PhD, FRCPC, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7. E-mail schiffe{at}IRCM.qc.ca
Abstract—In vitro experiments suggest that angiotensin II (Ang II) may cause growth via angiotensin type 1 (AT1) receptors and apoptosis via angiotensin type 2 (AT2) receptors. To answer the question of whether AT1 or AT2 receptor activation could induce apoptosis in the vasculature in vivo, Wistar rats were infused for 7 days with Ang II (120 ng · kg-1 · min-1 subcutaneously) and treated with the AT2 receptor antagonist PD 123319 (30 mg · kg-1 · d-1 subcutaneously) or the AT1 receptor antagonist losartan (10 mg · kg-1 · d-1 orally). Apoptosis in thoracic aorta was quantified by radiolabeled DNA laddering and by terminal deoxynucleotide transferase–mediated dUTP nick end-labeling. The expression of p53, bax, bcl-2, and caspase-3, which play critical roles in apoptotic signaling, was examined by Western blot analysis. The mRNA expression of AT1 and AT2 receptors was determined by reverse transcription–polymerase chain reaction. The increase in systolic blood pressure and aortic growth induced by Ang II infusion was completely prevented by losartan alone or losartan given with PD 123319, whereas PD 123319 resulted in a greater increase in systolic blood pressure and aortic growth than Ang II alone. Radiolabeled DNA laddering showed that Ang II infusion±losartan or PD 123319 significantly increased apoptosis (147±8%, 178±20%, and 238±41%, respectively, P<0.05 compared with control). Expression of bax and active forms of caspase-3 was increased in the Ang II+PD 123319 group, whereas the expression of p53 and bcl-2 was not significantly different in all groups. The expression of AT1 and AT2 receptor mRNA was downregulated by losartan and PD 123319, respectively. Thus, when AT1 or AT2 receptors are stimulated in vivo, apoptosis is enhanced in the media of blood vessels. In the case of AT1 receptor stimulation, this may occur secondary to vascular growth and modulate the latter. Both bax and caspase-3 participate in the pathways of apoptosis triggered by in vivo AT1 receptor stimulation.
Key Words: muscle, smooth, vascular • apoptosis • angiotensin II • p53 • cysteine proteases
This article has been cited by other articles:
 |
|
 |
|
  A. M. Briones, N. Rodriguez-Criado, R. Hernanz, A. B. Garcia-Redondo, R. R. Rodrigues-Diez, M. J. Alonso, J. Egido, M. Ruiz-Ortega, and M. Salaices Atorvastatin Prevents Angiotensin II-Induced Vascular Remodeling and Oxidative Stress Hypertension, July 1, 2009; 54(1): 142 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Redondo-Muller, M Stevanovic-Walker, S Barker, J R Puddefoot, and G P Vinson Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor Endocr. Relat. Cancer, March 1, 2008; 15(1): 277 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gurbanov and X. Shiliang The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 499 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, Y.-H. Song, J. Mohler, and P. Delafontaine ANG II induces apoptosis of human vascular smooth muscle via extrinsic pathway involving inhibition of Akt phosphorylation and increased FasL expression Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2116 - H2123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Verdecchia, F. Angeli, R. Gattobigio, and G. P. Reboldi Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur. Heart J., November 2, 2005; 26(22): 2381 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. De Ciuceis, F. Amiri, P. Brassard, D. H. Endemann, R. M. Touyz, and E. L. Schiffrin Reduced Vascular Remodeling, Endothelial Dysfunction, and Oxidative Stress in Resistance Arteries of Angiotensin II-Infused Macrophage Colony-Stimulating Factor-Deficient Mice: Evidence for a Role in Inflammation in Angiotensin-Induced Vascular Injury Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2106 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Bechara, A. Pelaez, A. Palacio, P. C. Joshi, C. M. Hart, L. A. S. Brown, R. Raynor, and D. M. Guidot Angiotensin II mediates glutathione depletion, transforming growth factor-{beta}1 expression, and epithelial barrier dysfunction in the alcoholic rat lung Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L363 - L370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, P. J. Rao, M. R. Castresana, and W. H. Newman TNF-{alpha} induces proliferation or apoptosis in human saphenous vein smooth muscle cells depending on phenotype Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H293 - H301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin and R. M. Touyz From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H435 - H446. [Full Text] [PDF]
|
|
|
|
 |
|
 B. I. Levy Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin-Angiotensin System Circulation, January 6, 2004; 109(1): 8 - 13. [Full Text] [PDF]
|
|
|
|
|
|
V. Grishko, V. Pastukh, V. Solodushko, M. Gillespie, J. Azuma, and S. Schaffer Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2364 - H2372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ruperez, O. Lorenzo, L. M. Blanco-Colio, V. Esteban, J. Egido, and M. Ruiz-Ortega Connective Tissue Growth Factor Is a Mediator of Angiotensin II-Induced Fibrosis Circulation, September 23, 2003; 108(12): 1499 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Werner and G. Nickenig AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A9 - A13. [Abstract] [PDF]
|
|
|
|
|
|
A. Virdis, M. F. Neves, F. Amiri, E. Viel, R. M. Touyz, and E. L. Schiffrin Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress Hypertension, October 1, 2002; 40(4): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. WALTHER, L. OLAH, C. HARMS, B. MAUL, M. BADER, H. HORTNAGL, H.-P. SCHULTHEISS, and G. MIES Ischemic injury in experimental stroke depends on angiotensin II FASEB J, February 1, 2002; 16(2): 169 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stoll, A. W.A. Hahn, U. Jonas, Y. Zhao, B. Schieffer, J. W. Fischer, and T. Unger Identification of a Zinc Finger Homoeodomain Enhancer Protein After AT2 Receptor Stimulation by Differential mRNA Display Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Bascands, J.-P. Girolami, M. Troly, I. Escargueil-Blanc, D. Nazzal, R. Salvayre, and N. Blaes Angiotensin II Induces Phenotype-Dependent Apoptosis in Vascular Smooth Muscle Cells Hypertension, December 1, 2001; 38(6): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ono, Y. Ono, A. Takanohashi, H. Matsuoka, and E. D. Frohlich Apoptosis and Glomerular Injury After Prolonged Nitric Oxide Synthase Inhibition in Spontaneously Hypertensive Rats Hypertension, December 1, 2001; 38(6): 1300 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis Hypertension, September 1, 2001; 38(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mezzano, M. Ruiz-Ortega, and J. Egido Angiotensin II and Renal Fibrosis Hypertension, September 1, 2001; 38(3): 635 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. N. Diep and E. L. Schiffrin Increased Expression of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} in Blood Vessels of Spontaneously Hypertensive Rats Hypertension, August 1, 2001; 38(2): 249 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. N. Diep, M. El Mabrouk, R. M. Touyz, and E. L. Schiffrin Expression of Cell Cycle Proteins in Blood Vessels of Angiotensin II-Infused Rats : Role of AT1 Receptors Hypertension, February 1, 2001; 37(2): 604 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. N. Diep, R. M. Touyz, and E. L. Schiffrin Docosahexaenoic Acid, a Peroxisome Proliferator-Activated Receptor-{alpha} Ligand, Induces Apoptosis in Vascular Smooth Muscle Cells by Stimulation of p38 Mitogen-Activated Protein Kinase Hypertension, November 1, 2000; 36(5): 851 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Structure and Mechanical Properties of Resistance Arteries in Hypertension : Role of Adhesion Molecules and Extracellular Matrix Determinants Hypertension, September 1, 2000; 36(3): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, S. Konig, B. Wittig, and J. Egido Angiotensin II Activates Nuclear Transcription Factor {kappa}B Through AT1 and AT2 in Vascular Smooth Muscle Cells : Molecular Mechanisms Circ. Res., June 23, 2000; 86(12): 1266 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-S. Tea, S. Der Sarkissian, R. M. Touyz, P. Hamet, and D. deBlois Proapoptotic and Growth-Inhibitory Role of Angiotensin II Type 2 Receptor in Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats In Vivo Hypertension, May 1, 2000; 35(5): 1069 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin, J. B. Park, H. D. Intengan, and R. M. Touyz Correction of Arterial Structure and Endothelial Dysfunction in Human Essential Hypertension by the Angiotensin Receptor Antagonist Losartan Circulation, April 11, 2000; 101(14): 1653 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Jeong Bae Park, H. D Intengan, and E. L Schiffrin Reduction of resistance artery stiffness by treatment with the AT1-receptor antagonist losartan in essential hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 40 - 45. [Abstract] [PDF]
|
|
|
|
|
|
Q. N. Diep, M. El Mabrouk, P. Yue, and E. L. Schiffrin Effect of AT1 receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1635 - H1641. [Abstract] [Full Text] [PDF]
|
|